445 related articles for article (PubMed ID: 20939065)
21. Mineralized tissues in hypophosphatemic rickets.
Robinson ME; AlQuorain H; Murshed M; Rauch F
Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510
[TBL] [Abstract][Full Text] [Related]
22. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
Kinoshita Y
Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
[TBL] [Abstract][Full Text] [Related]
23. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.
Larsson T; Marsell R; Schipani E; Ohlsson C; Ljunggren O; Tenenhouse HS; Jüppner H; Jonsson KB
Endocrinology; 2004 Jul; 145(7):3087-94. PubMed ID: 14988389
[TBL] [Abstract][Full Text] [Related]
24. A PAI-1 antagonist ameliorates hypophosphatemia in the Hyp vitamin D-resistant rickets model mouse.
Qian C; Ito N; Tsuji K; Sato S; Kikuchi K; Yoshii T; Miyata T; Asou Y
FEBS Open Bio; 2024 Feb; 14(2):290-299. PubMed ID: 38050660
[TBL] [Abstract][Full Text] [Related]
25. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
[TBL] [Abstract][Full Text] [Related]
26. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia.
Kumar R
Curr Opin Nephrol Hypertens; 2002 Sep; 11(5):547-53. PubMed ID: 12187320
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.
Wöhrle S; Henninger C; Bonny O; Thuery A; Beluch N; Hynes NE; Guagnano V; Sellers WR; Hofmann F; Kneissel M; Graus Porta D
J Bone Miner Res; 2013 Apr; 28(4):899-911. PubMed ID: 23129509
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.
Carpenter TO; Imel EA; Ruppe MD; Weber TJ; Klausner MA; Wooddell MM; Kawakami T; Ito T; Zhang X; Humphrey J; Insogna KL; Peacock M
J Clin Invest; 2014 Apr; 124(4):1587-97. PubMed ID: 24569459
[TBL] [Abstract][Full Text] [Related]
29. [Inhitibion of FGF23 activities as a possible new treatment for patients with FGF23-related hypophosphatemic diseases].
Kinoshita Y
Clin Calcium; 2016 Feb; 26(2):233-9. PubMed ID: 26813503
[TBL] [Abstract][Full Text] [Related]
30. Hypophosphatemic rickets and osteomalacia.
de Menezes Filho H; de Castro LC; Damiani D
Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):802-13. PubMed ID: 17117305
[TBL] [Abstract][Full Text] [Related]
31. Variable phosphate-mediated regulation of vitamin D metabolism in the murine hypophosphatemic rachitic/osteomalacic disorders.
Davidai GA; Nesbitt T; Drezner MK
Endocrinology; 1991 Mar; 128(3):1270-6. PubMed ID: 1999147
[TBL] [Abstract][Full Text] [Related]
32. [Updates on rickets and osteomalacia: anti-FGF23 antibody, a new therapeutic approach for hypophosphatemic rickets/osteomalacia].
Shimada T
Clin Calcium; 2013 Oct; 23(10):1469-75. PubMed ID: 24076645
[TBL] [Abstract][Full Text] [Related]
33. Anti-fibroblast growth factor 23 antibody therapy.
Fukumoto S
Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):346-51. PubMed ID: 24848934
[TBL] [Abstract][Full Text] [Related]
34. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
[TBL] [Abstract][Full Text] [Related]
35. Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice.
Zhang MY; Ranch D; Pereira RC; Armbrecht HJ; Portale AA; Perwad F
Endocrinology; 2012 Apr; 153(4):1806-16. PubMed ID: 22334725
[TBL] [Abstract][Full Text] [Related]
36. [Establishment of assay system for fibroblast growth factor (FGF)-23 and pathophysiological roles of FGF-23 in the development of hypophosphatemic diseases].
Fukumoto S; Nakahara K
Rinsho Byori; 2004 Jan; 52(1):51-4. PubMed ID: 14968560
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
38. New treatments for rare bone diseases: hypophosphatemic rickets/osteomalacia.
Marques JVO; Moreira CA; Borba VZC
Arch Endocrinol Metab; 2022 Nov; 66(5):658-665. PubMed ID: 36382755
[TBL] [Abstract][Full Text] [Related]
39. Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: A review of the role of iron.
Menon LP; Weinstein RS
Bone; 2020 Feb; 131():115137. PubMed ID: 31756522
[TBL] [Abstract][Full Text] [Related]
40. Management of X-linked hypophosphatemia in adults.
Lecoq AL; Brandi ML; Linglart A; Kamenický P
Metabolism; 2020 Feb; 103S():154049. PubMed ID: 31863781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
